Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.
Company Details
- Employees
- 32
- Founded
- -
- Address
- Oss, Noord-Brabant 5349 Ae , Nl
- in****@****yll.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- citryll.com
- Keywords
- Immunology, Therapeutics development, Neutrophil Extracellular Traps, Inflammatory diseases, Antibody development, Rheumatoid Arthritis, Hidradenitis Suppurativa.
- HQ
- Oss, Noord-Brabant
Citryll Questions
Citryll's website is citryll.com
Citryll's LinkedIn profile is https://nl.linkedin.com/company/citryll
Citryll has
32 employees.
View email and phone details for 32
employees at Citryll.
Citryll's industry is
Biotechnology Research
Citryll's top competitors are
Epitopea,
Antag Therapeutics,
Noema Pharma,
Newamsterdam Pharma Corporation,
Ladrx Corporation,
Chimerix, A Jazz Pharmaceuticals Company,
Nimble Therapeutics,
Nuvig Therapeutics Inc.,
Candel Therapeutics,
Cradle.
Citryll's support email address is info@citryll.com
Citryll's categories are Biotechnology Research
Citryll's founding year is 2015
